BIOMAT Database Logo BIOMAT Database Logo

The potent protein phosphatase 2A inhibitors aminocytostatins: new derivatives of cytostatin. 2021

Shigehiro Tohyama, and Manabu Kawada, and Hideyuki Muramatsu, and Masaki Hatano, and Hiroyuki Inoue, and Kazuaki Matoba, and Ryuichi Sawa, and Masayuki Igarashi
Institute of Microbial Chemistry, Microbial Chemistry Research Foundation (BIKAKEN), Shinagawa-ku, Tokyo, Japan. tohyamas@bikaken.or.jp.

Specific inhibitors of protein phosphatase 2A (PP2A) mediate anticancer effects by augmenting the tumor-killing activity of natural killer (NK) cells. In this study, new PP2A inhibitors, aminocytostatins A-E, were isolated from Kitasatospora sp. MJ654-NF4 and structurally characterized. Aminocytostatins are derivatives of cytostatin, which is a specific PP2A inhibitor isolated from the same organism, and aminocytostatins have a characteristic amino group within the lactone moiety. Compared to cytostatin, aminocytostatin A showed a stronger inhibitory activity against PP2A in vitro and augmented the tumor-killing activity of NK cells in vivo. Furthermore, a docking model was generated to demonstrate the favorable activities of aminocytostatin A.

UI MeSH Term Description Entries
D010755 Organophosphates Carbon-containing phosphoric acid derivatives. Included under this heading are compounds that have CARBON atoms bound to one or more OXYGEN atoms of the P( Organophosphate,Phosphates, Organic,Phosphoric Acid Esters,Organopyrophosphates,Acid Esters, Phosphoric,Esters, Phosphoric Acid,Organic Phosphates
D011485 Protein Binding The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments. Plasma Protein Binding Capacity,Binding, Protein
D011487 Protein Conformation The characteristic 3-dimensional shape of a protein, including the secondary, supersecondary (motifs), tertiary (domains) and quaternary structure of the peptide chain. PROTEIN STRUCTURE, QUATERNARY describes the conformation assumed by multimeric proteins (aggregates of more than one polypeptide chain). Conformation, Protein,Conformations, Protein,Protein Conformations
D011753 Pyrones Keto-pyrans.
D002470 Cell Survival The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability. Cell Viability,Cell Viabilities,Survival, Cell,Viabilities, Cell,Viability, Cell
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D013306 Streptomycetaceae A family of soil bacteria. It also includes some parasitic forms.
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D015394 Molecular Structure The location of the atoms, groups or ions relative to one another in a molecule, as well as the number, type and location of covalent bonds. Structure, Molecular,Molecular Structures,Structures, Molecular

Related Publications

Shigehiro Tohyama, and Manabu Kawada, and Hideyuki Muramatsu, and Masaki Hatano, and Hiroyuki Inoue, and Kazuaki Matoba, and Ryuichi Sawa, and Masayuki Igarashi
Synthesis of the protein phosphatase 2A inhibitor (4S,5S,6S,10S,11S,12S)-cytostatin.
May 2002, Angewandte Chemie (International ed. in English),
Shigehiro Tohyama, and Manabu Kawada, and Hideyuki Muramatsu, and Masaki Hatano, and Hiroyuki Inoue, and Kazuaki Matoba, and Ryuichi Sawa, and Masayuki Igarashi
Total synthesis and biological evaluation of the protein phosphatase 2A inhibitor cytostatin and analogues.
June 2004, Chemistry (Weinheim an der Bergstrasse, Germany),
Shigehiro Tohyama, and Manabu Kawada, and Hideyuki Muramatsu, and Masaki Hatano, and Hiroyuki Inoue, and Kazuaki Matoba, and Ryuichi Sawa, and Masayuki Igarashi
Cytostatin, an inhibitor of cell adhesion to extracellular matrix, selectively inhibits protein phosphatase 2A.
November 1999, Biochimica et biophysica acta,
Shigehiro Tohyama, and Manabu Kawada, and Hideyuki Muramatsu, and Masaki Hatano, and Hiroyuki Inoue, and Kazuaki Matoba, and Ryuichi Sawa, and Masayuki Igarashi
New bysspectin A derivatives as potent inhibitors of human carboxylesterase 2A.
November 2023, European journal of medicinal chemistry,
Shigehiro Tohyama, and Manabu Kawada, and Hideyuki Muramatsu, and Masaki Hatano, and Hiroyuki Inoue, and Kazuaki Matoba, and Ryuichi Sawa, and Masayuki Igarashi
1H-2,3-dihydroperimidine derivatives: a new class of potent protein tyrosine phosphatase 1B inhibitors.
December 2013, Molecules (Basel, Switzerland),
Shigehiro Tohyama, and Manabu Kawada, and Hideyuki Muramatsu, and Masaki Hatano, and Hiroyuki Inoue, and Kazuaki Matoba, and Ryuichi Sawa, and Masayuki Igarashi
Genetic manipulation of the biosynthetic process leading to phoslactomycins, potent protein phosphatase 2A inhibitors.
July 2006, Journal of industrial microbiology & biotechnology,
Shigehiro Tohyama, and Manabu Kawada, and Hideyuki Muramatsu, and Masaki Hatano, and Hiroyuki Inoue, and Kazuaki Matoba, and Ryuichi Sawa, and Masayuki Igarashi
Pyrrolo[2,3-c]azepine derivatives: a new class of potent protein tyrosine phosphatase 1B inhibitors.
July 2011, Bioorganic & medicinal chemistry letters,
Shigehiro Tohyama, and Manabu Kawada, and Hideyuki Muramatsu, and Masaki Hatano, and Hiroyuki Inoue, and Kazuaki Matoba, and Ryuichi Sawa, and Masayuki Igarashi
Purification and characterization of two potent heat-stable protein inhibitors of protein phosphatase 2A from bovine kidney.
February 1995, Biochemistry,
Shigehiro Tohyama, and Manabu Kawada, and Hideyuki Muramatsu, and Masaki Hatano, and Hiroyuki Inoue, and Kazuaki Matoba, and Ryuichi Sawa, and Masayuki Igarashi
2,4-Dihydroxychalcone derivatives as novel potent cell division cycle 25B phosphatase inhibitors and protein tyrosine phosphatase 1B inhibitors.
April 2014, Die Pharmazie,
Shigehiro Tohyama, and Manabu Kawada, and Hideyuki Muramatsu, and Masaki Hatano, and Hiroyuki Inoue, and Kazuaki Matoba, and Ryuichi Sawa, and Masayuki Igarashi
Identification of para-Substituted Benzoic Acid Derivatives as Potent Inhibitors of the Protein Phosphatase Slingshot.
December 2015, ChemMedChem,
Copied contents to your clipboard!